




Biomarkers Have Many Uses in Medicine


- Biomarkers important in clinical medicine include diagnostic, prognostic or physiologic status information, for example, vital signs, serum electrolytes, "x-rays" and other imaging modalities. Much of medical practice involves interpreting and monitoring biomarkers
- Markers of drug effect or response--the subject of this lecture--are a subset of the general class of biomarkers

















Biomarkers and Personalized Medicine


- In some cases a biomarker will be codeveloped with a therapeutic (e.g., for patient selection): this is termed codevelopment
- In some cases a biomarker will be sought to improve the benefit-to-risk for an alreadydeveloped therapy: this is a "rescue"
- In some cases a biomarker will be discovered to improve a long-used therapy: a "retrofit"


















- Use to assess whether drug has clinically significant efficacy: this is often faster than using clinical endpoint
- Surrogate endpoints may be used to support "accelerated approval" of a drug if the surrogate is deemed "reasonably likely" to predict a clinical endpoint of interest
 - Drugs approved under accelerated approval must undergo subsequent trials to demonstrate clinical efficacy
 - Only used in serious and life-threatening illnesses that lack acceptable therapy
- A few surrogate endpoints are acceptable for full approval (e.g., are "validated")



















Stimulating the Use of Biomarkers in Drug Development


- FDA's Critical Path Initiative: proposal to use consortia to qualify biomarkers through resource sharing
- Currently such consortia are ongoing in areas such as animal safety testing and overall biomarker development
- Clinical safety biomarkers of great interest










- Fourteen pharmaceutical companies joined consortium
- Agreed to cross-validate markers for organspecific drug injury
- Have submitted first qualification package to FDA for renal injury markers: precursor of new qualification process
- FDA and EMEA have accepted for use in animal studies














HIERARCHY OF BIOMARKERS* (Classic view)

<u>TYPE 0</u>: NATURAL HISTORY MARKER (Prognosis)

<u>TYPE I</u>: BIOLOGICAL ACTIVITY MARKER (Responds to therapy)

<u>TYPE II</u>: SINGLE OR MULTIPLE MARKER(S) OF THERAPEUTIC EFFICACY (Surrogate endpoint, accounts fully for clinical efficacy)

* Mildvan D, et al.: Clin Infect Dis 1997;24:764-74.

"Validation" of Biomarkers (e.g., for use as Surrogate

BIOLOGICAL PLAUSIBILITY

- EPIDMIOLOGIC EVIDENCE THAT MARKER IS A RISK FACTOR
- MARKER MUST BE CONSISTENT WITH PATHOPHYSIOLOGY
- MARKER MUST BE ON CAUSAL PATHWAY
- CHANGES IN MARKER REFLECT CHANGES IN PROGNOSIS

STATISTICAL CRITERIA

• CHANGES IN MARKER MUST BE CORRELATED WITH CLINICAL OUTCOME (but correlation does not equal causation)

(Not confounded by adverse drug effects)


ADDITIONAL SUPPORT FOR BIOMARKER as SURROGATE*


SUCCESS IN CLINICAL TRIALS

- EFFECT ON SURROGATE HAS PREDICTED OUTCOME WITH OTHER DRUGS OF SAME PHARMACOLOGIC CLASS
- EFFECT ON SURROGATE HAS PREDICTED OUTCOME FOR DRUGS IN SEVERAL PHARMACOLOGIC CLASSES

OTHER BENEFIT/RISK CONSIDERATIONS

- SERIOUS OR LIFE-THREATENING ILLNESS WITH NO ALTERNATIVE THERAPY
- LARGE SAFETY DATA BASE
- SHORT-TERM USE
- DIFFICULTY IN STUDYING CLINICAL ENDPOINT * Temple R: JAMA 1999;282:790-5.






Surrogate Endpoint Development: 1990s

- HIV epidemic spurred the use of new surrogate endpoints for antiretroviral therapy: highly controversial at first given CAST experience
- Rigorous statistical criteria for assessing correlation of candidate surrogate with clinical outcome were published*
- No surrogate EP has ever met these criteria

*Prentice. Stat in Med 8: 431, 1989







- Controversy over use of glycemic control as efficacy endpoint: rosiglitazone
 - Dispute is misguided
 - Real argument is over how much premarket cardiovascular safety data to accumulate
- Controversy over use of LDL cholesterol (as assessed by another biomarker, carotid artery intimal thickness on ultrasound): Vytorin

Fundamental Problems with the Current Conceptual Framework for Surrogate Endpoints

- There is no "gold standard" clinical outcome measurement concept of "ultimate" clinical outcome is flawed
- Survival: data show that desirability of longer survival dependent on quality of life, in many individuals' estimation.
- Generalizability of any single outcome measure (e.g., mortality) can be limited by trial parameters (e.g., who was entered)
- Confusion between desirability of prolonged observation (for safety and long term outcomes) and use of surrogate
- Can put "too many eggs" in the surrogate basket!





Biomarkers for Drug Effect in Clinical Practice

- Biomarker use
 - In drug development=qualification
 - As a surrogate endpoint = regulatory acceptance
 - In clinical practice as diagnostic=clinical utility, i.e., does use of the diagnostic add clinical value greater than its harm?
 - Often clinical utility of co-developed diagnostics will be demonstrated in the development program

Table 1 Questions related to biomarker development and validation

Activity	Question being addressed	Setting
Biomarker discovery and development	Is there an informative marker that correlates with a clinical state?	Laboratory
Analytical validation	Does the test measure the biomarker reliably?	Laboratory
Clinical validation	Does the test predict the clinical state?	Clinical research
Biomarker qualification	Does the test provide reliable information?	Drug development
Clinical utility evaluation	Is the test worth doing?	Health care
Surrogate end-point evaluation	Does the test predict the desired clinical response?	Drug development
Cost-effectiveness evaluation	Is the test worth paying for?	Reimbursement
Comparative effectiveness evaluation	Is the test worth doing in the real world, as compared with other options?	Health care

Summary Important public health need for development of additional biomarkers to target and monitor therapy This requires use in clinical trials during drug development Business model/regulatory path for such markers is not clear to industry Clarification and stimulus required

Summary Definitions for biomarkers, clinical outcomes and surrogate endpoints have been developed Further development of the model needed in order to increase use and utility of markers in drug development FDA has recently established a process to assist in evaluation and development of biomarkers used in drug development